TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

102 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

  • Dementia / Alzheimer'sParkinson's disease

    Phase 2 Trial of Tributyrin in People With Parkinson's Disease and Cognitive Impairments

    Testing whether a tributyrin supplement helps memory, thinking, and balance in adults with Parkinson

    📍 Domino's Farms · Ann Arbor, MI · Get directions →

    The goal of this clinical trial is to learn if taking a tributyrin supplement works to improve memory and thinking and walking and balance in adults with Parkinson disease Parkinson disease dementia. It will also learn about the safety of tributyrin supplementation.

    ✓ Study care freePhase 1Ages 45+Learn more →
  • Sickle cell disease

    A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)

    Testing different doses of DISC-3405 to check safety in sickle cell disease

    📍 University of Alabama at Birmingham · Birmingham, AL · +6 more US sites · Get directions →

    This is an open-label, multicenter, within-participant dose-escalation study examining up to 3 dose levels of DISC-3405 and will assess the safety, tolerability, PK, and PD of DISC 3405 in participants with sickle cell disease.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Dementia / Alzheimer's

    A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease

    Testing the safety and how a drug works in people with Alzheimer’s

    📍 Clinical Trial Site · Montreal, · Get directions →

    The purpose of this study is to: * Evaluate the safety and tolerability of intrathecal (IT) ALN-5288 in patients with Alzheimer's Disease (AD) * Evaluate the pharmacodynamic (PD) and pharmacokinetic (PK) effects of ALN-5288 after dose administration

    ✓ Study care freePhase 1Ages 40–80Learn more →
  • Sickle cell disease

    Escalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease

    Testing higher doses of VAS-101 in people with stable sickle cell disease

    💵 May compensate

    📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →

    Background: Sickle cell disease (SCD) is an inherited blood disorder. The disease affects the ability of red blood cells to carry oxygen.

    ✓ Study care freePhase 1Ages 18–90Learn more →
  • Dementia / Alzheimer's

    Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia

    Testing the safety and effects of two drugs for agitation in Alzheimer’s dementia

    📍 Esperanza Clinical · Murrieta, CA · +8 more US sites · Get directions →

    The goal of this clinical trial is to evaluate the safety and efficacy of EXV-802 and EXV-801 in treatment of agitation in participants with Alzheimer's Disease dementia.

    ✓ Study care freePhase 2Ages 55–90Learn more →
  • Dementia / Alzheimer's

    Rifaximin SSD in Dementia Trial

    Testing a new form of rifaximin to change gut microbes in people with dementia

    📍 Richmond VA Medical Center · Richmond, VA · Get directions →

    Using a new formulation of rifaximin, a non-absorbable antibiotic, to test if it can affect microbes in the gut of patients with dementia favorably.

    ✓ Study care freePhase 1Ages 65+Learn more →
  • Sickle cell disease

    A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide (CO) Therapeutic, in Subjects With Sickle Cell Disease (SCD)

    Testing the safety and how an oral carbon monoxide liquid works in sickle cell disease

    📍 Cevaxin - The Panama Clinic · Panama City, · Get directions →

    This is a multi-center, open label Phase 2a clinical trial in subjects with sickle cell disease to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of HBI-002, an orally administered liquid containing carbon monoxide (CO), with doses daily for 14 days.

    ✓ Study care freePhase 1Ages 18–55Learn more →
  • Dementia / Alzheimer's

    A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)

    Testing a gene therapy in people with a genetic form of frontotemporal dementia

    📍 The Ohio State University (OSU) Wexner Medical Center · Columbus, OH · +2 more US sites · Get directions →

    The goal of this clinical study is to learn about an investigational gene therapy product called AVB-101, which is designed to treat a disease called Frontotemporal Dementia with Progranulin Mutations (FTD-GRN). FTD-GRN is an early-onset form of dementia, a progressive brain disorder that affects behavior, language and movement.

    ✓ Study care freePhase 1Ages 30–75Learn more →
  • Dementia / Alzheimer's

    SV2A & TSPO PET Imaging Measures to Reveal Mechanisms of HIV Neuropathogenesis During Antiretroviral Therapy

    Using brain scans to study how HIV affects the brain during treatment

    📍 Yale School of Medicne, Neuro ID Research Program · New Haven, CT · Get directions →

    The purpose of this study is to longitudinally characterize and evaluate changes in synaptic density in the brain using novel positron-emission tomography (PET) scans; magnetic resonance imaging (MRI), and clinical laboratory markers associated with HIV-related injury in the central nervous system. This study will test hypotheses relating to the presence and mechanisms of aberrant brain structure at the synaptic level in living humans with virologically controlled HIV on antiretroviral therapy.

    ✓ Study care freePhase 1Ages 18–80Learn more →
  • Dementia / Alzheimer's

    Exploration of an Online Education Program to Support Caregivers' Knowledge Transfer

    Testing an online program to help dementia caregivers share what they learn

    📍 Texas Christian University · Fort Worth, TX · +1 more US site · Get directions →

    The overarching goal of this work is to determine methods that improve caregiver education about the behavioral and psychological symptoms (BPSD) of dementia. The specific goal of this project is to extend our prior work to evaluate the impact of our educational intervention on caregivers' ability to transfer knowledge about the management of ADRD to real-world applied examples.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Sickle cell disease

    The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease

    Testing rilzabrutinib for safety and effectiveness in sickle-cell disease

    📍 University of Alabama at Birmingham- Site Number : 8400003 · Birmingham, AL · +15 more US sites · Get directions →

    This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, flexible-adaptive, group-sequential study (Part A), followed by an open-label LTE period (Part B) to investigate the efficacy, and safety of rilzabrutinib in participants with sickle-cell disease (SCD). Study details include: * Study duration: a 52-week double-blind period (Part A), followed by an open-label LTE period (Part B).

    ✓ Study care freePhase 3Ages 10–65Learn more →
  • Dementia / Alzheimer's

    A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease

    Testing whether KarXT plus KarX-EC is safe and works for memory problems in Alzheimer’s disease

    📍 Healthy Brain Clinic · Long Beach, CA · +27 more US sites · Get directions →

    The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease

    ✓ Study care freePhase 3Ages 60–85Learn more →
  • Dementia / Alzheimer's

    A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

    Testing long-term safety and effectiveness of two medicines for agitation in Alzheimer’s dementia

    📍 Local Institution - 2609 · Chandler, AZ · +39 more US sites · Get directions →

    The purpose of this study is to evaluate the long-term efficacy and safety of combined formulation of xanomeline tartrate/trospium chloride in an immediate release (IR) capsule (KarXT) and xanomeline enteric capsules (KarX-EC) in participants with agitation associated with Alzheimer's Disease who completed the parent studies CN012-0023 or CN012-0024.

    ✓ Study care freePhase 3Ages 55–90Learn more →
  • Sickle cell disease

    Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease

    Testing whether extra arginine lowers pain in children with sickle cell

    📍 Children's Healthcare fo Atlanta at Hughes Spalding · Atlanta, GA · +1 more US site · Get directions →

    The purpose of this study is to determine whether giving extra arginine to patients with sickle cell disease seeking treatment for vaso-occlusive painful events (VOE) will decrease pain scores, decrease need for pain medications or decrease length of hospital stay or emergency department visit.

    ✓ Study care freePhase 1Ages 7–21Learn more →
  • Dementia / Alzheimer's

    Ferritin and Iron Burden in SAH sIRB

    Testing how iron and ferritin levels relate to brain injury after ruptured aneurysms with dementia

    📍 Univesity of Iowa Hospital and Clinics · Iowa City, IA · +1 more US site · Get directions →

    Ruptured cerebral aneurysms lead to subarachnoid hemorrhage (SAH),that has a high morbidity and mortality rate, the severity of which is predicted by the "Hunt-Hess grade" (HHG). SAH leads to iron (Fe) and hemoglobin (Hb) accumulation in the brain, which is toxic for neurons.

    ✓ Study care freePhase 1Ages 18–75Learn more →
  • Dementia / Alzheimer's

    Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease

    Studying whether ovarian hormones are linked to aging and Alzheimer’s risk in women

    📍 Mayo Clinic · Jacksonville, FL · +1 more US site · Get directions →

    The researchers are trying to determine whether ovarian hormones are associated with aging processes and with the risk of developing Alzheimer's disease in women.

    ✓ Study care freePhase 4Ages 60+WomenLearn more →
  • Dementia / Alzheimer's

    A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).

    Testing whether yearly donanemab helps people with dementia after a prior study

    📍 Banner Alzheimer's Institute · Phoenix, AZ · +39 more US sites · Get directions →

    The main purpose of this study is to determine if participants who previously took donanemab get clinical benefit when they receive annual doses. For each participant, the study will last up to 2.5 years and will include 6 visits.

    ✓ Study care freePhase 3Ages 55+Learn more →
  • Sickle cell disease

    RH Genotype Matched RBC Transfusions

    Testing whether matching donor red blood cells by RH type helps people with sickle cell who need

    📍 Children's Hospital of Philadelphia · Philadelphia, PA · Get directions →

    To determine the feasibility and efficacy of matching donor red cells by RH genotype for a cohort of chronically transfused patients with SCD.

    ✓ Study care freePhase 1Ages 1+Learn more →
  • Dementia / Alzheimer's

    A Trial Evaluating the Effect of NIO752 on Tau Synthesis Measured by a Process Known as SILK

    Testing a medicine in people with dementia to lower brain tau protein

    📍 Washington University in St. Louis · St Louis, MO · Get directions →

    This study will assess if drug (NIO752) reduces production of a protein, tau, by the brain. Normally tau maintains the internal skeleton of nerve cells.

    ✓ Study care freePhase 1Ages 21–80Learn more →
  • Dementia / Alzheimer's

    Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease

    Testing a treatment called SNK01 in people with moderate Alzheimer’s disease

    📍 Behavioral Research Specialists, LLC · Glendale, CA · +6 more US sites · Get directions →

    The goal of this clinical trial is to test SNK01 in participants with moderate Alzheimer's Disease. The main questions it aims to answer are: 1.

    ✓ Study care freePhase 1Ages 40–85Learn more →
  • Dementia / Alzheimer's

    A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

    Testing a drug called trontinemab for early Alzheimer’s disease dementia

    📍 Banner Alzheimer?s Institute · Phoenix, AZ · +32 more US sites · Get directions →

    The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment \[MCI\] to mild dementia due to AD).

    ✓ Study care freePhase 3Ages 50–90Learn more →
  • Dementia / Alzheimer's

    A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)

    Testing a treatment called KarXT plus KarX-EC for psychosis in people with Alzheimer's disease

    📍 Gilbert Neurology Partners/CCT Research · Gilbert, AZ · +5 more US sites · Get directions →

    The purpose of this study is to evaluate KarXT + KarX-EC as a treatment for psychosis associated with Alzheimer's disease.

    ✓ Study care freePhase 3Ages 55–90Learn more →
  • Sickle cell disease

    Transplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease

    Testing a one-time blood stem cell transplant using gene editing for severe sickle cell disease

    📍 University of California, Los Angeles · Los Angeles, CA · +1 more US site · Get directions →

    This is an open label, non-randomized, 2-center, phase 1/2 trial of a single infusion of sickle allele modified cluster of differentiation (CD34+) hematopoietic stem progenitor cells (HSPCs) in subjects with in subjects ≥12 years old to 35 years old severe Sickle Cell Disease (SCD). The study will evaluate the hematopoietic stem cell transplantation (HSCT) using CRISPR/Cas9 edited red blood cells (known as CRISPR\_SCD001 Drug Product).

    ✓ Study care freePhase 1Ages 12–35Learn more →
  • Dementia / Alzheimer'sMultiple sclerosis (MS)

    Exploring the Utility of [18F]3F4AP for Demyelination Imaging

    Testing how an imaging tracer works in people with memory loss and multiple sclerosis

    📍 Yale University PET Center · New Haven, CT · Get directions →

    The overall objective is to obtain an assessment of the pharmacokinetics of \[18F\]3F4AP in healthy volunteers and subjects with demyelinating diseases such as mild cognitive impairment (MCI), Alzheimer's Disease (AD), Multiple Sclerosis (MS), Spinal Cord Injury (SCI) and Spinal radiculopathy (SR).

    ✓ Study care freePhase 1Ages 18–90Learn more →
  • DepressionDementia / Alzheimer's

    Aβ Dynamics in LLMD

    Testing how treating depression may change brain markers linked to Alzheimer’s

    📍 NYU Langone Health · New York, NY · +1 more US site · Get directions →

    This study will examine the biological factors that may modulate the relationship between depression and the development of Alzheimer's disease (AD). Since the direction of causation between depression and the biological factors associated with AD is unknown, the only way to understand cause and associated risk is to treat the depressive symptoms and examine the effects on AD biomarkers.

    ✓ Study care freePhase 4Ages 60+Learn more →
  • Dementia / Alzheimer's

    Epidemiology and Biomarker Study in Alzheimer's Disease

    Studying how memory changes over time and blood test results in people with dementia

    📍 Care Access - Houston · Houston, TX · Get directions →

    Study AACU determines rates of cognitive worsening in participants within elevated and not elevated plasma P-tau217 cohorts. Participation in AACU will last approximately 7 years.

    ✓ Study care freePhase 3Ages 55–75Learn more →
  • Sickle cell disease

    Cannabidiol in Sickle Cell Disease

    Testing twice-daily cannabidiol doses for people with sickle cell disease

    📍 Icahn School of Medicine at Mount Sinai · Manhattan, NY · Get directions →

    Randomized, placebo-controlled, double masked, dose finding study of twice daily cannabidiol given at 3 dose levels, 200mg, 400mg, and 600mg, compared to placebo for 4 weeks.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Dementia / Alzheimer's

    Study of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease

    Testing how a new medicine works in healthy adults and early Alzheimer’s disease

    📍 Research Site 3 · East York, Ontario · Get directions →

    Study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of ARO-MAPT-SC compared to placebo in adult healthy volunteers and in participants with early Alzheimer's disease (AD), defined as mild cognitive impairment due to AD and mild AD dementia.

    ✓ Study care freePhase 1Ages 18–80Learn more →
  • Sickle cell disease

    Prophylactic Transfusion In Pregnant in Women With Sickle Cell Disease

    Testing whether routine red blood cell transfusions in pregnancy reduce sickle cell flare-ups or

    📍 Grady Health System · Atlanta, GA · Get directions →

    The goal of this study is to determine if there is a positive effect of prophylactic red blood cell (RBC) transfusion of leukoreduced, ABO, Rh (D/Cc/Ee) and Kell matched blood compared to standard of care on the number of episodes of acute sickle cell disease (SCD) manifestations or pregnancy-related complications requiring acute health care encounters (acute care/ER/Hospital visits) or resulting in death over the entirety of pregnancy until 2 months post-partum in women with SCD. RBC transfusion is the only disease-modifying therapy for pregnant women with SCD, and it is considered a standard treatment option however, there exists no consensus on the role of transfusion therapy in preventing SCD-related pregnancy complications.

    ✓ Study care freePhase 4Ages 18+WomenLearn more →
  • Dementia / Alzheimer's

    📍 Endeavor Health Systems · Evanston, IL · Get directions →

    CMK-0301 is a multi-site, randomized clinical trial to evaluate the safety and efficacy of \[F-18\]Flornaptitril-PET (F-18 FNT-PET) for the prediction of clinical progression of Mild Cognitive Impairment (MCI) with either Suspected Chronic Traumatic Encephalopathy (CTE) or Alzheimer's Disease (AD). The primary objectives of the study are to: (1) To determine the accuracy of F-18 FNT-PET in prediction of clinical decline and (2) To assess the safety and tolerability of F-18 FNT.

    ✓ Study care freePhase 3Ages 45+Learn more →
  • Sickle cell disease

    Gene Editing For Sickle Cell Disease

    Testing whether gene editing is safe for people with sickle cell disease

    📍 St. Jude Children's Research Hospital · Memphis, TN · Get directions →

    This study is being done to test the safety of a new treatment called gene editing in Sickle Cell Disease (SCD) patients and to see if a single dose of this genetically modified cellular product will increase the amount of a certain hemoglobin called fetal hemoglobin (HbF) and help reduce the symptoms of SCD. Primary Objective * To assess the safety of autologous infusion of clustered regularly interspaced palindromic repeats (CRISPR)/ CRISPR associated protein (Cas9)-edited CD34+ hematopoietic stem and progenitor cells (HSPCs) in patients with severe SCD.

    ✓ Study care freePhase 1Ages 18–24Learn more →
  • Sickle cell disease

    Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease

    Testing a single pneumococcal vaccine dose in children with sickle cell disease

    📍 Site # 8400006 · Atlanta, GA · +4 more US sites · Get directions →

    The purpose of this study is to measure whether PCV21 vaccine (investigational pneumococcal vaccine) is safe and can help the body to develop germ-fighting agents called "antibodies" (immunogenicity) compared with 20vPCV (licensed pneumococcal vaccine) when given as a single dose to children aged 2 to 17 years with sickle cell disease who had received or not a previous vaccination with pneumococcal conjugate or pneumococcal polysaccharide vaccine.

    ✓ Study care freePhase 3Ages 2–17Learn more →
  • Dementia / Alzheimer's

    A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

    Testing a treatment (KarXT plus KarX-EC) for memory problems in Alzheimer’s dementia

    📍 Fullerton Neurology and Headache Center · Fullerton, CA · +29 more US sites · Get directions →

    The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease

    ✓ Study care freePhase 3Ages 60–85Learn more →
  • Dementia / Alzheimer's

    TREAD: Time Restricted Eating Intervention for Alzheimer's Disease

    Testing time-limited eating to see if it improves sleep and brain changes in early Alzheimer’s or

    📍 Shiley Marcos Alzheimer's Disease Center · San Diego, CA · Get directions →

    The goal of this clinical trial is to learn if restricting the time of eating to allow for prolonged fasting at night may reduce sleep disturbances, cognitive decay, and pathology in patients diagnosed with Mild Cognitive Impairment (MCI) or early to moderate Alzheimer's disease (AD). It will also learn about the feasibility of practicing 14 h of nightly fasting in this group of older adults.

    ✓ Study care freePhase 1Ages 60+Learn more →
  • Dementia / Alzheimer's

    PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620

    Comparing tau brain scan images in different types of dementia

    📍 Perelman Center for Advance Medicine · Philadelphia, PA · Get directions →

    The investigators will compare \[18F\]-PI-2620 tau PET scans from patients with frontotemporal lobar degeneration (FTLD), patients with non-amnestic presentations of Alzheimer's disease (naAD), and demographically matched cognitively normal subjects.

    ✓ Study care freePhase 3Ages 18+Learn more →
  • Dementia / Alzheimer's

    A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)

    Testing the safety and effects of ACI-24.060 in Alzheimer’s and Down syndrome

    📍 Barrow Neurological Institute · Phoenix, AZ · +12 more US sites · Get directions →

    The purpose of this study is to assess the safety, tolerability, immunogenicity and pharmacodynamic effects of ACI-24.060 in subjects with prodromal Alzheimer's disease and in non-demented adults with Down syndrome.

    ✓ Study care freePhase 1Ages 35–85Learn more →
  • Dementia / Alzheimer's

    A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)

    Testing a drug combination to treat agitation in adults with Alzheimer’s

    📍 Chandler Clinical Trials, LLC · Chandler, AZ · +39 more US sites · Get directions →

    The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.

    ✓ Study care freePhase 3Ages 55–90Learn more →
  • Dementia / Alzheimer's

    Nicotinic Acid for the Treatment of Alzheimer's Disease

    Testing how well extended-release niacin reaches spinal fluid in dementia

    📍 IU Health Neuroscience Center · Indianapolis, IN · Get directions →

    Increased dietary intake of niacin is correlated with reduced risk of Alzheimer's Disease and age-associated cognitive decline. The goal of this study is to collect data on the penetration of commercially available, FDA approved, extended-release niacin into the spinal fluid.

    ✓ Study care freePhase 1Ages 60–85Learn more →
  • Dementia / Alzheimer's

    A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease

    Testing whether a new drug is safe in people with early Alzheimer’s

    📍 K2 Medical Research, LLC · Maitland, FL · +5 more US sites · Get directions →

    The main purpose of this study is to evaluate the safety of LY3954068 in participants with early symptomatic Alzheimer's Disease (AD). The study will also investigate how much LY3954068 gets into the bloodstream and will test the effects of LY3954068 on markers of AD.

    ✓ Study care freePhase 1Ages 50–85Learn more →
  • Dementia / Alzheimer's

    Deep Repetitive Transcranial Magnetic Stimulation (rTMS) of the Precuneus for Alzheimer Disease (AD)

    Testing deep rTMS on a brain area for people with probable Alzheimer dementia to see if it is safe

    📍 UCLA TMS Clinical and Research Service · Los Angeles, CA · Get directions →

    The goal of this clinical trial is to learn if using deep repetitive transcranial magnetic stimulation (rTMS) targeting the precuneus is feasible, tolerable, and potentially efficacious for memory in Probable Alzheimer's Dementia. Previous work studying rTMS in Alzheimer's is mixed, but recent work studying rTMS of the precuneus is encouraging for both its short-term and long-term effects.

    ✓ Study care freePhase 1Ages 60–100Learn more →
  • Sickle cell disease

    A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia

    Testing long-term treatment with a new medicine for sickle cell or thalassaemia

    📍 Univ of Alabama Birmingham · Birmingham, AL · +38 more US sites · Get directions →

    Etavopivat is a new medicine under development for treating blood disorders like sickle cell disease and thalassaemia. Sickle cell disease and thalassaemia are inherited blood disorders that affect haemoglobin.

    ✓ Study care freePhase 3Ages 2+Learn more →
  • Sickle cell disease

    A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease

    Testing how BMS-986470 affects the body and safety in sickle cell disease

    📍 University of Alabama at Birmingham · Birmingham, AL · +18 more US sites · Get directions →

    The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, pH and food effect, and preliminary efficacy of BMS-986470 in healthy volunteers and participants with sickle cell disease.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Sickle cell disease

    Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors

    Testing a partial stem cell transplant from matched donors for severe sickle cell disease or

    📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →

    This is a non-ablative (partial) stem cell transplant for patients with severe sickle cell disease or beta-thalassemia requiring red cell transfusions. The intensity of the transplant is slightly increased from our previous transplant regimens.

    ✓ Study care freePhase 1Ages 4–65Learn more →
  • Sickle cell disease

    Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease

    Testing how safe escalating doses of fostamatinib are in people with stable sickle cell disease

    📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →

    Background: Sickle cell disease (SCD) is a genetic disease that causes the body to produce abnormal ( sickled ) red blood cells. SCD can cause anemia and life-threatening complications in the lungs, heart, kidney, and nerves.

    ✓ Study care freePhase 1Ages 18–65Learn more →
  • Sickle cell disease

    Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies

    Testing gene editing in stem cells for severe sickle cell disease

    📍 Boston Children's Hospital · Boston, MA · Get directions →

    A promising approach for the treatment of genetic diseases is called gene therapy. Gene therapy is a relatively new field of medicine that uses genetic material (mostly DNA) from the patient to treat his or her own disease.

    ✓ Study care freePhase 1Ages 13–40Learn more →
  • Dementia / Alzheimer's

    A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease

    Testing the safety and effects of ABBV-1758 in people with Alzheimer’s disease given as injections

    📍 Irvine Center for Clinical Research /ID# 277752 · Irvine, CA · +10 more US sites · Get directions →

    Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elderly population. Clinical symptoms of the disease may begin with occasional forgetfulness such as misplacement of items, forgetting important dates or events, and may progress to noticeable memory loss, increased confusion and agitation, and eventually, loss of independence and non-responsiveness.

    ✓ Study care freePhase 1Ages 50–90Learn more →
  • Dementia / Alzheimer's

    Door-Through-Door Companion Rideshare Technology for Individuals With Alzheimer's Disease and Related Dementias (AD/ADRD)

    Testing a rideshare with a trained driver to help people with dementia get to medical visits

    📍 Onward Health HQ · San Leandro, CA · Get directions →

    The goal of this pilot randomized controlled trial is to assess the impact of D2D rideshare services with a trained companion driver on the rate of medical appointments for older adults and individuals with AD/ADRD. Participants will be assigned either door-through-door (D2D) rideshare or curb-to-curb (C2C) rideshare services.

    ✓ Study care freePhase 1Ages 60+Learn more →
  • Dementia / Alzheimer's

    A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)

    Testing the safety and side effects of Zunveyl in people with mild to moderate Alzheimer’s

    📍 Tekton Research Saint Louis Psychiatry · St Louis, MO · Get directions →

    The primary purpose of this study is to evaluate the safety and tolerability of Zunveyl® over 12 weeks of routine clinical use in adults with mild to moderate Alzheimer's disease.

    ✓ Study care freePhase 4Ages 50+Learn more →
  • Dementia / Alzheimer's

    AV-1980R (Tau Vaccine) in Preclinical Alzheimer's Disease (TAURUS-1980)

    Testing a vaccine for early Alzheimer’s disease biomarkers for safety

    📍 Comprehensive Center for Brain Health · Boca Raton, FL · +2 more US sites · Get directions →

    This is a Phase 1, multicenter, randomized, double-blind, placebo-controlled, multiple dose-escalating trial to evaluate the safety, tolerability, and immune response of AV-1980R, an investigational vaccine targeting tau protein, in participants with preclinical Alzheimer's disease. Up to 48 cognitively unimpaired adults aged 65-80 with biomarker evidence of early Alzheimer's disease will be enrolled into three ascending dose cohorts.

    ✓ Study care freePhase 1Ages 65–80Learn more →
  • Dementia / Alzheimer's

    📍 Montreal Neurological Institute Clinical Research Unit · Montreal, Quebec · Get directions →

    This study aims to evaluate the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics following administration of RO7812653 in participants with eAD.

    ✓ Study care freePhase 1Ages 50–75Learn more →
  • Sickle cell disease

    SCD Stem Cell Mobilization and Apheresis Using Motixafortide

    Testing whether motixafortide is safe and can raise stem cells in people with sickle cell disease

    📍 University of Alabama at Birmingham · Birmingham, AL · +2 more US sites · Get directions →

    This study is being done to see if the study drug, motixafortide, is safe in participants with sickle cell disease (SCD). Investigators also want to see if the drug will help the body increase the number of stem cells that can be collected for possible future transplant use.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Sickle cell disease

    📍 University Of Alabama · Birmingham, AL · +13 more US sites · Get directions →

    A phase III, multi-center, randomized, placebo-controlled, double-blind study to assess efficacy and safety of crizanlizumab (5 mg/kg) versus placebo, with or without hydroxyurea/hydroxycarbamide therapy, in adolescent and adult Sickle Cell Disease patients with frequent vaso-occlusive crises.

    ✓ Study care freePhase 3Ages 12–100Learn more →
  • Dementia / Alzheimer's

    A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

    Testing trontinemab for safety and effectiveness in early Alzheimer’s disease dementia

    📍 University of Alabama at Birmingham · Birmingham, AL · +34 more US sites · Get directions →

    The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment \[MCI\] to mild dementia due to AD).

    ✓ Study care freePhase 3Ages 50–90Learn more →
  • Dementia / Alzheimer's

    PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)

    Testing brain scans that measure PDE4 in people with dementia

    📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →

    Background: About 5 million adults in the United States have age-related brain disorders. These include Alzheimer disease (AD), mild cognitive impairment (MCI), and other dementias.

    ✓ Study care freePhase 1Ages 50–100Learn more →
  • Sickle cell disease

    Effectiveness of Nontraditional Hydroxyurea Algorithms: Novel and Clinical Evaluations (ENHANCE)

    Testing different ways to use hydroxyurea for treating sickle cell anemia

    📍 Cincinnati Children's Hospital Medical Center · Cincinnati, OH · Get directions →

    The main reason for this research study is to learn more about hydroxyurea and the treatment of sickle cell anemia (SCA). Hydroxyurea is a medication that has been studied for many years and has been shown to provide benefits for people with SCA.

    ✓ Study care freePhase 4Ages 1+Learn more →
  • Dementia / Alzheimer's

    Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

    Screening people who may be eligible for Alzheimer’s disease studies for dementia

    📍 University of Alabama at Birmingham · Birmingham, AL · +39 more US sites · Get directions →

    This study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies.

    ✓ Study care freePhase 3Ages 50–90Learn more →
  • Dementia / Alzheimer's

    Lemborexant for Insomnia in a Patient With Dementia: An N-of-1 Trial

    Testing a sleep medicine for insomnia symptoms in a person with dementia

    📍 Nova Scotia Health · Halifax, Nova Scotia · Get directions →

    Insomnia is a highly common, chronic disorder that is distressful for the patient but also for caregivers and can give rise to a heavy burden on the healthcare team. Sleeping aids like benzodiazepines and other sedatives (e.g., zolpidem, zopiclone) have been widely used to help treat insomnia.

    ✓ Study care freePhase 4Learn more →
  • Dementia / Alzheimer's

    Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease

    Testing a treatment with IL-2 and semaglutide in people with Alzheimer's

    📍 Houston Methodist Research Institute · Houston, TX · Get directions →

    Alzheimer's disease (AD) is the most common cause of dementia. Despite major research efforts, effective treatments that slow or stop disease progression remain limited.

    ✓ Study care freePhase 1Ages 50–86Learn more →
  • Dementia / Alzheimer's

    A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

    Testing a medicine for psychosis in adults with moderate to severe Alzheimer’s

    📍 Local Institution - 1227 · Chandler, AZ · +39 more US sites · Get directions →

    The purpose of this study is to evaluate the safety and efficacy of KarXT in adult participants with mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD.

    ✓ Study care freePhase 3Ages 55–90Learn more →
  • Dementia / Alzheimer's

    Low-Dose Radiotherapy for Alzheimer's Disease

    Testing low-dose whole-brain radiation safety in people with Alzheimer’s or dementia

    📍 Renaissance Institute of Precision Oncology & Radiosurgery · Winter Park, FL · Get directions →

    To evaluate the safety and tolerability of low-dose whole brain radiotherapy (WBRT) delivered as an induction course of 0.3 Gy × 10 fractions (3.0 Gy total) followed by 12 months of monthly maintenance LDRT (0.3 Gy × 10 fractions; 3.0 Gy total) in patients with Alzheimer's disease or dementia with inflammatory components

    ✓ Study care freePhase 1Ages 50+Learn more →
  • Showing the first 60 of 102. Add filters or a location to narrow down.